Several recently published studies suggest that Chlamydia pneumoniae may represent a risk factor for atherosclerosis or its complications. In order to establish whether C. pneumoniae is causally linked to atherosclerotic diseases, clinical intervention trials may be needed. However, to identify eligible subjects with a persistent C. pneumoniae infection and to monitor the effect of antibiotic therapy, there is a need for a reliable diagnostic marker. Blood-based polymerase chain reaction assays may be of value for identifying patients persistently infected with C. pneumoniae and for assessing the microbiologic efficacy of antichlamydial therapy in clinical intervention trials.
|Original language||English (US)|
|Journal||Journal of Infectious Diseases|
|Issue number||6 SUPPL. 3|
|State||Published - 2000|
ASJC Scopus subject areas
- Immunology and Allergy
- Infectious Diseases